Video: Toward Safe Use of Opioids

Roflumilast Cream 0.15% Demonstrates Safety, Tolerability in Individuals With Atopic Dermatitis With Prior Treatment Failures

RAD 2025: Renowned AD investigator Kircik provides the history behind the classwide black box warning, highlights JAK inhibitor efficacy, and toplines exciting AD research.

Safety and Local Tolerability of Roflumilast Cream 0.15% in Patients With Atopic Dermatitis and Prior Topical Treatment Limitations /image credit Oregon Health and Science University

Long-Term Roflumilast Data Show Durable Efficacy in Young Children and Adults with Atopic Dermatitis

RAD 2025: Safety and tolerability of roflumilast cream 0.15% was demonstrated in a pooled subgroup analysis of phase 3 study participants unresponsive to or intolerant of previous topical therapy.

Dupilumab Improves Asthma Control, HRQoL Regardless of Comorbid Th2 Inflammatory Disease

RAD 2025: Arcutis Biotherapeutics will present promising long-term data on roflumilast cream, focused on effectiveness and safety for treating atopic dermatitis in young children.

May 21st 2025

Postpartum Inpatient HPV Vaccination Significantly Boosts Uptake at Urban Hospital, Study Finds

Data from the global RAPID registry provide real-world support for dupilumab efficacy in youths and adults with uncontrolled asthma and with or without CRS and/or nasal polyposis.

Prenatal Substance Use Counseling: Missed Opportunities for Intervention

An intervention that included educational materials for clinicians on a multidisciplinary prenatal and postpartum care team helped drive acceptance.

Q&A: JAK Inhibitor Safety in Context and the Rich Atopic Dermatitis Pipeline, with Leon Kircik, MD

Pregnant patients' perceptions do not match clinician certainty on abstinence counseling during pregnancy, and clinicians may not be asking patients about their partner's substance use.

Related Content

Leon Kircik, MD ;Grace Halsey

June 13th 2025

Roflumilast Cream 0.15% Demonstrates Safety, Tolerability in Individuals With Atopic Dermatitis With Prior Treatment Failures

RAD 2025: Renowned AD investigator Kircik provides the history behind the classwide black box warning, highlights JAK inhibitor efficacy, and toplines exciting AD research.

Long-Term Roflumilast Data Show Durable Efficacy in Young Children and Adults with Atopic Dermatitis

RAD 2025: Safety and tolerability of roflumilast cream 0.15% was demonstrated in a pooled subgroup analysis of phase 3 study participants unresponsive to or intolerant of previous topical therapy.

Dupilumab Improves Asthma Control, HRQoL Regardless of Comorbid Th2 Inflammatory Disease

RAD 2025: Arcutis Biotherapeutics will present promising long-term data on roflumilast cream, focused on effectiveness and safety for treating atopic dermatitis in young children.

May 21st 2025

Postpartum Inpatient HPV Vaccination Significantly Boosts Uptake at Urban Hospital, Study Finds

Data from the global RAPID registry provide real-world support for dupilumab efficacy in youths and adults with uncontrolled asthma and with or without CRS and/or nasal polyposis.

Prenatal Substance Use Counseling: Missed Opportunities for Intervention

An intervention that included educational materials for clinicians on a multidisciplinary prenatal and postpartum care team helped drive acceptance.